Skip to main content
Clinical Trials/CTRI/2024/07/071196
CTRI/2024/07/071196Not yet recruitingPhase 4

Comparison of Effectiveness and Safety of Dapagliflozin and Empagliflozin in Type 2 Diabetes Mellitus - NI

Dr Manu Arya0 sites0 target enrollmentStarted: TBDLast updated:

Trial Snapshot

Phase
Phase 4
Status
Not yet recruiting
Sponsor

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Inclusion Criteria

  • All Patients with Type2 diabetes mellitus as per ADA guidelines
  • Patients of either gender with age more than 18 years.
  • Patients giving written informed consent.

Exclusion Criteria

  • Pregnant & lactating women.
  • Patients not complying with the study protocol.
  • Patients with underlying comorbid conditions like recurrent UTI, chronic renal diseases.
  • Patients with co-morbid conditions like malignancy, psychiatric disorders, substance abuse
  • Patients with concomitant medications likely to interfere with glycemic control e.g.: Steroids, Beta-blockers, Thiazide Diuretics

Investigators

Sponsor
Dr Manu Arya

Similar Trials